Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Announces Overnight Marketed Equity Offering

Business Wire May 17, 2022

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 27, 2022

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

Business Wire April 13, 2022

Appili Therapeutics (TSX:APLI) secures US$3.6M loan, license and distribution agreement with Long Zone Holdings

Caroline Egan  March 29, 2022

Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings

Business Wire March 29, 2022

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

Business Wire February 28, 2022

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022

Business Wire February 14, 2022

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

Business Wire February 8, 2022

Appili Therapeutics - Press Release Correction

Business Wire December 23, 2021

Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners

Business Wire December 22, 2021

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

Business Wire November 19, 2021

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer

Business Wire November 12, 2021

IIROC Trade Resumption - APLI

PR Newswire November 12, 2021

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus(TM)

Business Wire November 12, 2021

IIROC Trading Halt - APLI

PR Newswire November 11, 2021

Appili Therapeutics Closes $7M Overnight Offering

John Ballem  October 14, 2021

Appili Therapeutics Announces Closing of Public Offering of $7,000,220

Business Wire October 14, 2021

Appili Therapeutics (TSX:APLI) announces $7 million overnight offering

Trevor Abes  October 13, 2021

IIROC Trade Resumption - APLI

PR Newswire October 7, 2021

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

Business Wire October 7, 2021